The study aim was to identify early (within 14 days) and late changes (by 3 months) in breast cancer gene expression profiles associated with neoadjuvant therapy with letrozole. RNA from sequential tumour biopsies in 54 patients was analyzed on microarrays; changes were determined by frequency, magnitude and significance analyses. Substantially more genes were changed at 3 months (1503) than at 14 days (237). Early changed genes were associated with cell cycle (downregulation), blood vessel development and extracellular matrix (upregulation); late changes included 'cellular metabolic process', 'generation of precursor metabolites and energy' (decreased) and 'cell adhesion' 'biological adhesion' (increased). A striking difference between the early and late changes was the general location of downregulated genes-nuclear structures at 14 days and mitochondria after 3 months. These changes in gene expression profiles provide a new and important database by which to understand molecular mechanisms of letrozole in breast cancers.
Introduction
Letrozole is a third-generation aromatase inhibitor, which is highly effective in postmenopausal women with oestrogen receptor-positive breast cancer. [1] [2] [3] [4] The drug is specific and its only primary effect is to block oestrogen biosynthesis. [5] [6] [7] It is an ideal agent by which to study the molecular effects of oestrogen deprivation. These properties have been exploited in a neoadjuvant protocol in which letrozole was given to postmenopausal women while the primary tumour remained within the breast. Tumour was taken before, after 10-14 days and after 3 months of treatment. Extracted RNA was then assayed by microarray analysis to identify genes the expression of which was influenced by oestrogen deprivation. Results have already been presented on changes occurring in the first 10-14 days of treatment. 8 However, neither the dynamics of effects nor longer-term effects of treatment have been defined. The purpose of the present study was, therefore, to assess the effects of letrozole on RNA expression in serial samples from the same primary breast cancers taken before and after days and months of treatment.
Materials and methods

Patients
Details of the patient population have been published previously. 8, 9 A consecutive series of postmenopausal women with large primary oestrogen receptor-positive breast cancer were recruited from a single centre (Edinburgh Breast Unit). Patients were treated neoadjuvantly with letrozole (Femara, 2.5 mg, Novartis Pharma AG, Basel, Switzerland) given daily for 3 months. The study was approved by the local ethics committee (2001/W/BU/09 and 2001/W/BU/10). All patients gave informed consent. Patients were routinely interviewed and specifically questioned by a research nurse about taking letrozole to have indirect proof of compliance.
Tumour processing and RNA extraction Multiple core biopsies were taken with a 14-gauge needle 10 before (at diagnosis) and after 10-14 days; tumour was also available after 3 months treatment. Biopsies were snapfrozen and stored in liquid nitrogen. Frozen sections were taken before RNA extraction to confirm the presence of cancerous tissue within the specimens. Only samples in which the malignant component comprised at least 20% of the cross-sectional area were processed further; this value was chosen on an arbitrary basis, believing that values below that would be unlikely to provide an adequate cancer 'signal'. It was decided prospectively not to micro-dissect or otherwise artificially enrich biopsies for the malignant component because of the wish to include signals that might be affected by letrozole in non-malignant components. Frozen biopsies were pulverized using a U2 microdismembranator (Braun Biotech, Melsungen, Germany). Total RNA was extracted from the frozen tissue powder using TRI reagent (Sigma, Poole, Dorset, England) according to the manufacturer's recommendations. RNA was additionally purified on RNeasy mini columns (Qiagen, Crawley, West Sussex, UK); quality was evaluated on Agilent Bioanalyser 2100 (Agilent Technologies UK, Wokingham, Berkshire, UK).
RNA amplification, reverse transcription and microarray hybridization RNA (500 ng) was subject to two rounds of amplification.
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Complementary RNA was converted into double-stranded DNA and biotinylated complementary RNA generated using the Enzo kit (Affymetrix, Santa Clara, CA, USA). Biotinylated complementary RNA was fragmented and added to Affymetrix HG_U133A chips as described in the standard protocol outlined in the GeneChip Expression Analysis Technical Manual (Affymetrix). After sample hybridization, microarrays were washed with a custom Genomics Institute of the Novartis Research Foundation (GNF) chip washer, and scanned with an Affymetrix 3000 laser scanner (Affymetrix).
Microarray data analysis
Primary microarray data are available from the Gene Expression Omnibus (National Center for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov/geo/) with series number GSE20181.
Processing of raw data
The arrays used were hgu133a (Affymetrix), each comprising 22283 features. A total of 181 arrays were QC analyzed, using the arrayQualityMetrics Bioconductor package (http:// bioconductor.org/biocLite.R). 12 Arrays were scored on the basis of six metrics-maplot, boxplot, heatmap, spatial, rle and nuse. Four arrays failed two or more of the QC metrics, and were removed from subsequent analyses. The remaining arrays were filtered to include only features called 'Present' on more than 30 percent of the arrays, as calculated by the Affymetrix MAS5 algorithm. Normalization of the remaining 10109 features across all arrays was achieved using the robust multi-array average expression measure 13 that results in expression measures (summarized intensities) in log base 2.
Processing of normalized data
Genes most changed with treatment were identified using three different approaches on the basis of the (i) frequency of changes, (ii) magnitude of changes and (iii) statistical significance of changes assessed by linear models analysis as implemented in the limma Bioconductor package. 14 
Frequency of change
Numbers of upregulated and downregulated cases were calculated for each probe set. Downregulation was defined as a decrease in numerical value for a probe in individual cases, provided the pretreatment call was positive. Upregulation was defined as an increase in numerical value for individual probes, provided that the post-treatment call was positive. Pairs in which both pretreatment and posttreatment calls were either absent or marginal were regarded as no change irrespective of the numerical value allocated.
Magnitude of changes Post-treatment:pre-treatment ratios were calculated for each probe set and the median and interquartile ranges calculated. Lists of upregulated and downregulated genes were derived from the median changes. To take into account the present, absent or marginal calls generated by Affymetrix MAS5 algorithm, probe sets that were called as absent or marginal in more than 30% of post-treatment cases were excluded from the upregulated genes. Similarly, genes in which more than 30% of the calls were absent/marginal in the pre-treatment specimen were excluded from the downregulated list.
Statistically significant changes
Group to group comparisons were undertaken using linear modelling and sample pairing. Empirical Bayesian analysis was applied (including vertical (within a given comparison) P-value adjustment for multiple testing, which controls for false discovery rate). The Bioconductor package limma was used. 15 Present, absent and marginal calls were taken into account as described above.
Clustering K-mean partitioning was performed using Gene Cluster 3.0 and Java Tree-View software. 16, 17 The number of groups used during partitioning was based on the visual assessment of hierarchical dendrograms and on the previous analysis of the data set. 8 
Gene ontology
Functions of the changed genes were analyzed using GOEAST toolkit for Gene Ontology (GO) enrichment analysis. 18 GO terms enriched in the lists of up-and downregulated genes were identified by w 2 -test with Bonferroni correction for multiple testing (Po0.05).
Results
Derivation of database
A total of 79 patients were enrolled into the study. Of these, 25 cases were excluded on account of (i) biopsies having less than 20% malignancy or (ii) failing to yield sufficiently good-quality RNA or (iii) sub-optimal microarray at one or more study time points. The database from the remaining 54 cases was subjected to further bioinformatics analysis. A flowchart illustrating the study design is shown in Figure 1 .
Changes in gene expression with therapy
Three approaches have been used to characterize the gene expression changes occurring with therapy. These were to (i) identify genes that were consistently upregulated or downregulated irrespective of the magnitude of effect, (ii) discover genes with the greatest median magnitude of change irrespective of the number of cases and (iii) identify genes whose expression was most significantly changed with therapy.
Day 0 to day 14 (i) Gene probes with consistent direction of change: Using the criteria of change in at least 42 of 54 (75%) patients, 70 downregulated and 47 upregulated genes were identified. These are listed in Supplementary File 1a.
(ii) Magnitude of changes: Gene probes with median change 41.5-fold comprised 24 downregulated and 24 upregulated probe sets as identified in Supplementary File 1b. The largest fold-changes were observed in classical oestrogen-regulated genes (such as KIAA0101 and trefoil factors) and in cell-cycle genes (such as CDC2, CKS2 and CCND1) that were downregulated. Genes with most upregulated magnitude of expression were associated with extracellular matrix components (collagens, DCN and MMP2) and included some genes potentially regulated by the PPAR signaling pathway (such as CD36 and FABP4).
(iii) Statistical significance of changes: 201 (132 downregulated and 69 upregulated) probe sets significantly changed after 2 weeks of treatment were identified by univariate linear regression analysis (adjusted Po0.001). Details of individual genes are presented in Supplementary File 1c.
Interrelationships. Venn diagrams illustrating interrelationships between the genes identified by the three approaches are depicted in Figure 2a . Only 21 genes (13 downregulated and 8 upregulated) were identified by all three approaches; these are listed in Table 1 . Merging data produced a total of 237 probes (140 downregulated and 97 upregulated) that were subject to gene ontology and cluster analysis.
Functional gene analysis and ontology. Genes downregulated after 10-14 days of treatment were functionally associated with cell-cycle progression, particularly mitosis ( Figure 3a ). In contrast, upregulated genes were associated with more general processes, such as organ and system development including those related to vasculature, immunity and extracellular matrix (Figure 3b ). In terms of cellular components, chromosome and nuclear terms were identified. A full list of the identified GO terms is shown in Supplementary KIAA0101 and AGR2) and proliferation-associated genes (CDC2, CKS2 and CCND1) that were downregulated, whereas stromal signature genes (collagens, MMP2, DCN and pleiotrophin) were upregulated.
(iii) Gene probes significant at adjusted Po0.001: These are listed in Supplementary File 2c and included 768 downregulated and 713 upregulated genes.
Interrelationships. These are illustrated in Figure 2b . There were 97 probes (31 downregulated and 66 upregulated) identified by all three approaches (Table 2) . Merging data produced a total of 1503 genes (781 downregulated and 722 upregulated), which were analzsed for functionality, gene ontology and clustering.
Functional gene analysis and ontology. The biological function GO terms most enriched amongst genes downregulated after 3 months included 'cellular metabolic processes', 'generation of precursor metabolites and energy' and cell cycle-associated terms (Figure 3a) . Biological function terms, enriched in upregulated genes included 'multi-cellular organism development' and cell adhesionassociated terms (Figure 3b ). The top changed GO terms for downregulated genes were associated with mitochondria, whereas the GO terms for upregulated genes were associated with extracellular matrix (Supplementary File 4).
Day 14 to 3 months (i) Gene probes with a consistent direction of change:
A total of 52 probes (25 downregulated and 27 upregulated genes) were consistently changed between 2 weeks and 3 months of treatment (Supplementary File 3a). Several WNTassociated genes (DKK3, TCF7L2, NCOR2 and CDH9) were among the upregulated probes.
(ii) Magnitude of changes: Gene probes with median change 41.5-fold are listed in Supplementary Table 3b . These comprised 10 downregulated and 22 upregulated. The largest fold-change downregulated genes included haemoglobins. The upregulated genes included genes associated with adhesion to extracellular matrix.
(iii) Gene probes significant at adjusted Po0.001: These are listed in Supplementary File 3c. In total 269 array features were identified (106 downregulated and 163 upregulated). It is interesting that the most significant loci were CYR61 cysteine-rich angiogenic inducer 61 (an extracellular, matrixassociated signaling molecule that promotes the adhesion of endothelial cells through interaction with integrin and augments growth factor-induced DNA synthesis) and EGR1 (which belongs to the EGR family of C2H2-type zinc-finger proteins, and is a nuclear protein that functions as a transcriptional regulator).
Interrelationships. These are depicted in Figure 2c . Only eight genes (two downregulated and six upregulated) were identified by all three approaches (Table 3) . Merging data produced a total of 269 genes (106 downregulated and 163 upregulated), which were analyzed for functionality, gene ontology and clustering.
Functional gene analysis and ontology. The most enriched GO terms were associated with transcription/RNA metabolism (downregulated) and cell adhesion, electron transport and other mitochondrion-related functions (upregulated). Details are documented in Supplementary File 4. 
Chronology and patterns of changes
The interrelationships among changes in expression between day 0 and day 14, day 0 and 3 months and day 14 and 3 months are shown in Venn diagrams ( Figure 4 ). Of genes changed at 2 weeks, most were also identified at 3 months (131 of 140 downregulated and 75 of 97 upregulated). These characteristics reflect early and sustained changes with treatment ( Figure 4 : red lines). Similarly, the majority of genes changed between 14 days and 3 months also appeared within the 0-3 month category (81 of 106 downregulated and 117 of 163 upregulated), representing a relatively late treatment effect (Figure 4 blue line). However, most of the genes identified as being changed at 3 months did not appear in the other time subgroups (569 of 781 downregulated and 534 of 722 upregulated) suggesting more marginal but continuous effects that require the full '3 months' observation period to become perceptible (Figure 4 green line). The remaining phenotypes appear to be associated with transient or variable changes. Thus, there were nine downregulated and 22 upregulated genes in which changes were apparent at 2 weeks, but not at 3 months (grey lines in Figure 4 ); treatment appears to have produced early but transient changes in these genes. A final subgroup was identified in which changes (25 downregulation and 46 upregulation) were evident only in the period between 2 weeks and 3 months. This suggests that the major effect of treatment are late, but may have been preceded by smaller changes in the opposite direction (see yellow lines in Figure 4 ). The identities of genes in each of the subgroups are presented in Supplementary Files 5 and 6.
Tumour subgrouping by cluster analysis Figure 5a shows K mean partitioning performed on the cumulative total of 237 (140 downregulated and 97 upregulated) gene probes identified as changed after 14 days. Although downregulated genes were uniformly changed throughout the cases, tumours could be split into three groups on the basis of the changes in the upregulated genes that were less consistent. The groups comprised (i) 13 cases (cluster 1) in which upregulation was marked, (ii) 32 cases (cluster 2) with moderate upregulation and (iii) 9 cases (cluster 3) in which genes identified as being normally upregulated within the total group were paradoxically downregulated or unchanged. A heat map illustrating changes in expression of the 781 downregulated and 722 upregulated genes at 3 months for the three clusters is shown in Figure 5b . It can be seen that the differences between clusters 1 and 2 are reduced, but cluster 3 is still clearly different. Individual cases also switched phenotype; thus, at 3 months cases 68 and 69 in cluster 1 become similar to tumours within cluster 3 and conversely cases 16, 42 and 56 within cluster 3 would be classified within clusters 1 and 2. 
Discussion
This study is the first report of dynamic changes in genomewide expression patterns in breast cancers during treatment with the aromatase inhibitor, letrozole. The present paper represents a major addition to our previous reports on changes occurring after 14 days of treatment with letrozole, 8, 9 by including data on expression profiles in the same breast cancers after 3 months of treatment. This has allowed us not only to examine longer-term effects, but to examine the dynamic patterns of genetic changes in sequential breast cancer samples.
Our study exploits a major advantage of using a neoadjuvant protocol in which sequential samples can be taken from individual breast cancers during treatment. The study design, therefore, permits the dynamics of expression changes to be monitored in matched samples from the same tumours rather than examining effects at a single time point in different cases (an important consideration given the known inter-tumour heterogeneity of breast cancers). The only known endocrine effect of third-generation inhibitors is to inhibit specifically the aromatase enzyme that is crucial for oestrogen biosynthesis. The sequential assessments are, therefore, likely to identify primary effects of oestrogen Cysteine and glycine-rich protein 2 deprivation (at 14 days) and then the secondary consequences of primary molecular changes (at 3 months). These results clearly indicate that the nature of genes changed by letrozole will be heavily influenced by time of exposure to the drug. In this respect, it is essential that further studies are performed to determine treatment effects beyond 3 months for which there appears to be no published results. Furthermore, because biopsies were taken from tumours being treated in situ, the breast cancers were exposed to the precise endocrinology resulting from the use of aromatase inhibitors in postmenopausal women. It should be noted that the use of aromatase inhibitors in cultured cell lines or animals bearing xenografts often poorly reproduce this endocrinology. Because endocrine effects may not be apparent or consistent in all breast cancers, it was also important to study the effects of letrozole in a relatively large number of tumours (certainly in excess of the number of cell lines or animal models currently available).
The tumours included in the present analyses are largely those described in our previous publications. 9 However four cases were not included because tumour was not available for analysis at 3 months. Thus the present analysis of the 2-week data was performed on a slightly different population to those previously published. In this respect, it is important that the present results on 2-week changes were essentially similar to those previously published. 8 Genes changing with treatment have been identified by three different bioinformatic approaches. Consideration was given to (i) consistent changes that occurred in most tumours, (ii) highest median magnitudes of change and (iii) statistical significance of the changes. As is summarized in Figures 2a-c the methods identify different genes illustrating that the type of data processing will influence derived results. It is interesting that only a small proportion of the statistically significant changes were observed on the basis of either consistency or amplitude of change. This is probably because the statistical method examines group-togroup differences, whereas the other criteria are patient specific. If markers are to be used routinely to detect treatment changes, it is important that they are not simply significantly changed according to a specific statistical model, but the genes are also changed consistently and at high amplitude. We have, therefore, listed genes fulfilling these criteria in Tables 1-3 . However, when performing analyses of functionality and clustering, we have merged lists of genes identified by each of the bioinformatic approaches rather than risk excluding genes influenced by treatment.
A major observation in the present study was that the number of changed genes was substantially higher after 3 months than after 14 days of treatment. As most of the genes changed at 14 days were also identified at 3 months, the extra genes at the later time point may represent secondary events occurring in response to primary molecular changes. This would be compatible with changes in tumour morphology and pathology that were rarely seen at 14 days, but were frequent after 3 months. Hence, late genetic changes are likely to reflect not only phenotypic intracellular events but also effects on cellular populations. The observed genetic changes may occur in multiple or different tumour compartments. For example, alterations in the expression of extracellular matrix-associated genes (including collagens, matrix metalloproteases and adhesion molecules) may not primarily take place in the malignant component of the tumour, but reflect the reactive rearrangements in stroma.
There were interesting similarities and differences between changes evident at 14 days and 3 months. In terms of similarities, many of the genes changed at both 14 days and 3 months coded for cell-cycle proteins, regulators and markers of proliferation; GO terms for downregulated genes also included 'cell cycle' and 'M phase' at both time points. These observations are also consistent with the protein expression of markers, such as Ki67 that are markedly decreased by letrozole at both 14 days and 3 months. 19 However, there were marked differences in gene expression changes at day 14 and 3 months as reflected in their GO terms. Thus, 'cellular metabolic process' and 'generation of precursor metabolites and energy' were the most significantly enriched downregulated terms at 3 months, but did not appear in the top 10 enriched terms at day 14 ( Figure  3a) . It is interesting that extracellular matrix-associated GO terms altered between 2 weeks and 3 months of treatment: terms 'regulation of response to stimuli' and 'response to wounding' were identified only at 2 weeks, whereas 'cell adhesion' and 'biological adhesion' were detected only at 3 months. There was also a major change in the cellular localization of the affected genes-nuclear and chromosomal location being apparent at 14 days, whereas mitochondrial association (inner mitochondrial membrane) predominated at 3 months. These results clearly indicate how the nature of genes changed by letrozole is influenced by time of exposure to the drug.
Because gene expression profiles were studied at three consecutive time points from the same tumours, it was possible to examine the dynamics of gene expression and categorize genes according to patterns of change (see Figure   4) . Consequently, the genes could be split into major groups. The largest grouping comprised genes whose expression changed over 3 months without being identified as changed either within the first 2 weeks or last 10 weeks of treatment (green line, Figure 4 ). These appear to be genes on which treatment has relatively marginal effects so that the full study period of 3 months is needed to detect changes. Other major groups included (i) genes which showed early sustained changes-expression was changed at both 0-14 days and 0-3 months timeframes (red line, Figure 4) (ii) genes whose expression changed late into treatment-effects seen at 14 days-3 month and 0-3 months timeframes, but not 0-14 days (blue lines) (iii) a minority of genes with transient changes (that is, changes at 0-14 days, but not at 3 months-grey lines) and (iv) genes in which major effects occurred late, but apparently may have been preceded by relatively minor changes in the opposite direction (yellow lines, Figure 4) .
Clustering of cases by gene changes revealed heterogeneity between tumours. Thus, using genes changed at 14 days, tumours could be separated into subgroups according to the degree of gene upregulation (Clusters 1 and 2 Figure 5a ) and a subgroup of tumours with paradoxical decrease in genes initially identified as being upregulated in the whole tumour population (Cluster 3). By applying the 3-month changes to this clustering differences between tumour groups were generally reduced but a minority of tumours still showed paradoxical changes (Figure 5b ). The tumours with paradoxical changes were not necessarily the same cases at 14 days and 3 monthsa further illustration of differences in effects of letrozole between breast cancers.
Although it is beyond the scope of this paper, the clinical, pathological and proliferative responses of the tumours in this study are known and the patterns of gene expression may be related to these parameters. Results in relation to day 0, day 14 and the change between these time points have already been published, 9, 20 The corresponding relationships on expression at 3 months and dynamic changes are complex and will be published elsewhere. However, it should be emphasized that genes most changing with treatment as identified in this study will generally not be the best predictors of such responses, because they are likely to be changed in both tumours responding and not responding to treatment. Furthermore, as discussed above, expression changes at 3 months (when responses are clinically and pathologically manifest) may have occurred as a result of clinical, pathological or proliferative changes.
In summary, the pharmacogenomic information described in this paper represents the first database on dynamic transcriptional profiles of clinical breast cancer specimens taken at multiple times of treatment with an aromatase inhibitor. The lists of changed genes generated by the study provide a valuable new resource for future work in terms of (i) understanding the molecular effects of aromatase inhibitors and oestrogen deprivation and (ii) optimizing, individualizing and monitoring the use of aromatase inhibitors in the treatment of breast cancer patients.
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